AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Berenberg raised AbbVie’s price target from $165 to $195 while maintaining a Hold rating. The firm increased its estimates due to stronger-than-expected immunology sales. AbbVie’s stock has surged 22% ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie has surged 9.9% in the past month, outperforming the S&P 500’s 7.4% decline. Earnings estimates suggest a solid ...

After hours: March 12 at 7:57:57 PM EDT Loading Chart for ABBV ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...

Forbes contributors publish independent expert analyses and insights. Building a platform to do the job of 1 million analysts ...

ABBV) have crossed above the average analyst 12-month target price of $207.60, changing hands for $209.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ...